Unresectable Chordoma clinical trials at University of California Health
1 research study open to eligible people
open to eligible people ages 12 years and up
This phase II trial studies how well nivolumab and relatlimab work in treating participants with chordoma that has spread to other places in the body. Monoclonal antibodies, such as nivolumab and relatlimab, may interfere with the ability of tumor cells to grow and spread.
Our lead scientists for Unresectable Chordoma research studies include Arun Singh.